Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing
A study by researchers at Mayo Clinic, USA, published this week in the Journal of…
Prompt colonoscopy should follow up positive bowel cancer tests
A prompt colonoscopy should be provided to all patients with positive fecal immunochemical test (FIT)…
DNA discovery can lead to new types of cancer drugs
Cells can both survive and multiply under more stress than previously thought, shows research from…
How does Keytruda treat melanoma and why is it so costly? by Prof Ian Olver
Ian Olver, University of South Australia Keytruda® (pembrolizumab) is the latest drug to be registered in Australia for the treatment…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.